The Philadelphia Neurodevelopmental Cohort: A publicly available resource for the study of normal and abnormal brain development in youth

Theodore D. Satterthwaite a,⁎,1, John J. Connolly b,1, Kosha Ruparel a, Monica E. Calkins a, Chad Jackson a, Mark A. Elliott c, David R. Roalf a, Ryan Hopson a, Karthik Prabhakaran a, Meckenzie Behr b, Haijun Qiu b, Frank D. Mentch b, Rosetta Chiavacci b, Patrick M.A. Sleiman b,d, Ruben C. Gur a,c,e, Hakon Hakonarson b,d,1, Raquel E. Gur a,c,1

⁎ Corresponding author at: Brain Behavior Laboratory, 10th Floor, Gates Building, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.
E-mail address: sattertt@upenn.edu (T.D. Satterthwaite).
1 Contributed equally.

A B S T R A C T

The Philadelphia Neurodevelopmental Cohort (PNC) is a large-scale study of child development that combines neuroimaging, diverse clinical and cognitive phenotypes, and genomics. Data from this rich resource is now publicly available through the Database of Genotypes and Phenotypes (dbGaP). Here we focus on the data from the PNC that is available through dbGaP and describe how users can access this data, which is evolving to be a significant resource for the broader neuroscience community for studies of normal and abnormal neurodevelopment.

© 2015 Elsevier Inc. All rights reserved.

Introduction

The Philadelphia Neurodevelopmental Cohort (PNC) is a large-scale study of child development that incorporates rich multi-modal neuroimaging, genetics, and detailed clinical and cognitive phenotyping (Satterthwaite et al., 2014a). The PNC is a resource that responds to a paradigm shift in the field of psychiatric neuroscience, where major mental illnesses are increasingly conceptualized as disorders of development (Insel, 2010; Insel, 2009; Casey et al., 2014; Paus et al., 2008). Together, the multi-level data of the PNC provides a resource to delineate patterns of normal brain development, describe how abnormal patterns of brain development are related to cognitive dysfunction and psychiatric symptomatology, and most ambitiously explore how genetics impacts brain and behavioral development and predisposes individuals to risk of psychiatric symptoms.

While a collaborative team in Philadelphia collected the data, comprehensive analysis that leverages this broad research agenda is best accomplished by sharing the data with the scientific community. As previously emphasized (Biswal et al., 2010; Gorgolewski et al., 2013; Mennes et al., 2012; Milham, 2012; Nooner et al., 2012; Bis et al., 2012; Stein et al., 2012), large publicly available datasets are a prerequisite for the collaboration necessary to gain traction towards understanding complex phenomena such as the neurodevelopmental origins of psychiatric illness. Furthermore, the unique data of PNC is certain to outstrip the expertise of any single research group; appropriate utilization of the PNC as a resource will require the perspectives of many investigators with complementary skill sets. Accordingly, when the PNC was designed it was explicitly conceptualized as a publicly available resource, to be shared through the Database of Genotypes and Phenotypes (dbGaP; 13). While we have previously described the design of the PNC in detail (Satterthwaite et al., 2014a), here we focus on the publicly available PNC datasets in dbGaP and associated data access procedures.

Study overview

The PNC was funded by the National Institutes of Mental Health through the American Reinvestment and Reconstruction Act of 2009 as a 2-year collaborative study between the Center for Applied Genomics and Pediatric Mental Health. The PNC was designed it was explicitly conceptualized as a publically available resource, to be shared through the Database of Genotypes and Phenotypes (dbGaP; 13). While we have previously described the design of the PNC in detail (Satterthwaite et al., 2014a), here we focus on the publicly available PNC datasets in dbGaP and associated data access procedures.
Genomics (CAG) at the Children’s Hospital of Philadelphia (CHOP; PI: Hakon Hakonarson) and the Brain Behavior Laboratory at the University of Pennsylvania (Penn, PI: Raquel E. Gur). Importantly, the study capitalized on the resources available through CAG, including a subject pool of (at that time) approximately 50,000 genotyped youths. Critically, approximately 78% of the genotyped youths in the CAG database had provided consent to be re-contacted for future research, allowing for subjects to be approached for recruitment to the PNC. The participants were from the greater Philadelphia area and contacted after stratification by sex, age, and ethnicity. The institutional review boards of the University of Pennsylvania and the Children’s Hospital of Philadelphia approved all study procedures. Overall, the PNC data in dbGaP includes information from 9498 children ages 8–21, who were evaluated with a detailed neuropsychiatric evaluation. The psychiatric and neurocognitive assessment was conducted at home (68.8% of participants) or in the laboratory (31.2%), according to participant preference and suitability of the home environment for assessment. Assessment was administered by trained assessors, who recorded information regarding the quality of the testing environment and subject engagement. A sub-sample received multi-modal neuroimaging performed on a separate study visit at Penn. The average interval between imaging and assessment was 3.3 months. All clinical, neurocognitive and genetic data were placed in dbGaP; the multi-modal neuroimaging data currently available in dbGaP consists of cross-sectional data from 1000 subjects.

To participate in the PNC, minimal inclusion criteria were required. These included the ability to provide signed informed consent (for participants under age 18, assent and parental consent were required), English proficiency, and the physical and cognitive abilities to engage in psychiatric and cognitive phenotyping procedures. Most PNC participants came for primary care in one of the CHOP-affiliated pediatric clinics throughout the Delaware Valley, but the overall sample also included children with more complicated illnesses who received care at CHOP. However, on screening for participation in the neuroimaging component, subjects with medical problems that could impact brain function were excluded. These included major medical problems that could affect brain function, including major severe medical problems (malignancy, immunological disorders, renal/hepatic compromise), neurological conditions (stroke, meningitis, epilepsy, brain tumor, traumatic brain injury), or endocrine disorders (including thyroid or adrenal abnormalities). Additionally, participants with impaired vision or hearing, implanted ferrous metal, unverified metal exposure, claustrophobia, or other contraindications to MRI were also excluded.

**PNC data available in dbGaP**

PNC data available in dbGaP is composed of a) a super-set of 9498 subjects with medical, psychiatric, neurocognitive, and genomic data and b) a sub-set of 1000 subjects who received multi-modal neuroimaging. The super-set of subjects grew to 9498 in early 2015 from the original 8741 subjects released in January 2014. At present, this constitutes a static archive of data collected in the initial cross-sectional acquisition phase of the PNC. However, as described in further detail below (see Future Directions section) the PNC is an ongoing study and dbGaP archive will be updated annually. Below, we briefly describe the clinical, neurocognitive, and imaging phenotypes available. Genotyping procedures are not discussed here, but the genotyping pipeline used at CAG has been previously described in detail (Pinto et al., 2010; Glessner et al., 2009) and further information can be accessed at www.caglab.org. The vast majority of the samples were genotyped on the 550HH and 610Q SNP arrays from Illumina that overlap in over 500,000 SNPs and are readily imputable to multi-million variants. Further information regarding clinical assessment, cognitive testing, and imaging procedures is provided in PNC manuscripts that have used these data types (Satterthwaite et al., 2012a; Satterthwaite et al., 2013a; Satterthwaite et al., in press; Satterthwaite et al., 2014b; Satterthwaite et al., 2014c; Roalf et al., 2014; Ingalhalikar et al., 2014; Gur et al., 2014; Erus et al., in press; Calkins et al., 2014; Gur et al., 2012; Moore et al., 2014; Robinson et al., 2015), as well as in the data manifest, data dictionary, and phenotype description files available in dbGaP. The compressed size of a single subject’s data is approximately 250 MB.

**Demographic, medical, and psychopathology assessment**

Demographic, medical, and psychopathology histories were assessed using a structured computerized instrument, called GOASSESS (Calkins et al., 2014). GOASSESS was developed from a modified version of the Kiddie-Schedule for Affective Disorders and Schizophrenia (Kaufman et al., 1997). In addition to standard demographic data, the psychopathology screener allows symptom and criterion-related assessment of mood, anxiety, behavioral, eating disorders, psychosis spectrum symptoms, and substance use history. Both subject and collateral informant data were acquired for children ages 11–17; for children under age 11 only collateral data was acquired, whereas for young adults older than age 18 only subject report was acquired. As described in detail elsewhere (Calkins et al., in press), Bachelor’s and Master’s level assessors underwent a common 25-hour training protocol that included didactic sessions, assigned readings, and supervised pair-wise practice. They were certified for independent assessments through a standardized procedure requiring observation by a certified clinical observer who rated the proficiency of the assessor on a 60-item checklist of interview procedures (Calkins et al., in press).

Psychopathology data from GOASSESS is represented in dbGaP as nearly 600 individual item-level responses. To assure the quality of interview data, each assessment underwent a computerized error-checking algorithm that identified areas requiring assessor’s attention, and a standardized post-administration review process by certified clinical reviewers. Results were reported to assessors and supervisors. A computerized chart review module provided management tools for the comprehensive review process for supervisors, reviewers, and assessors, as well as an automated check to ensure that all steps were completed successfully. Data were checked, cleaned, and corrected prior upload to dbGaP.

In addition to data on psychopathology, GOASSESS included over 150 self-report items regarding medical history, including specific review of systems questions regarding major organ systems (neurologic, cardiac, pulmonary gastrointestinal, endocrine, etc; see Merikangas et al. (2015)). Although neuroimaging screening sought to exclude individuals with a history of major medical problems, subsequent analysis of this medical inventory revealed that a small percentage of the imaged sample did indeed have a history of medical disorders that could impact brain function, or had a clinical abnormality of brain structure that was encountered incidentally (Gur et al., 2013). Thus, in published studies from our group, medical items from GOASSESS (in concert with data from the electronic medical record, see below) were used to perform a second round of medical exclusions.

**Computerized neurocognitive battery**

The Penn computerized neurocognitive battery (Penn CNB) has been widely used in large-scale studies of psychiatric illness and collaborative genomics studies (Calkins et al., 2010; Greenwood et al., 2011). As part of the PNC, the Penn CNB was simplified for the pediatric population and shortened to a 1-hour administration time (Gur et al., 2014; Gur et al., 2012; Gur et al., 2010). Shorter administration time was achieved without increased measurement error through combination of classical psychometric as well as item response theory methods (Roalf et al., 2014; Gur et al., 2014; Gur et al., 2012; Moore et al., 2014). The CNB used as part of the PNC consisted of 14 tests that were adapted from tasks applied in functional neuroimaging studies to evaluate a broad range of cognitive domains. These domains include executive control (abstraction and mental flexibility, attention, working
memory), episodic memory (verbal, facial, spatial), complex cognition (verbal reasoning, nonverbal reasoning, spatial processing), social cognition (emotion identification, emotion intensity differentiation, age differentiation) and sensorimotor and motor speed. Except for the latter two tests that only measure speed, data in dbGaP includes both accuracy and speed information for each trial type in each test. This information, along with normative performance metrics, was used to generate validation codes for each test and the CNB as a whole. Clinical, cognitive, and demographic data are available for all subjects with neuroimaging data, and can be downloaded from dbGaP as a comma-separated values (.csv) file.

### Multi-modal neuroimaging

All imaging data from the PNC was acquired at Penn, on a single scanner, in a short period of time that did not span any software or hardware upgrades. All MRI scans were acquired on a single 3 T Siemens TIM Trio whole-body scanner using the VB17 revision of the Siemens software. Signal excitation and reception were obtained using a quadrature body coil for transmit and a 32-channel head coil for receive. Gradient performance was 45 mT/m, with a maximum slew rate of 200 T/m/s. Due to the short study timeline and lack of a development phase, with the exception of perfusion imaging sequence, product sequences were used. The MRI protocol was comprised of scans designed to obtain information on brain structure, perfusion, structural connectivity, resting state functional connectivity, working memory function, and emotion differentiation (i.e. non-oblique). The total scanning time of the entire protocol was 50 min. 32 s.

Sequence parameters and the number of subjects available for each scan type in dbGaP are displayed in Table 1. The scanning protocol used a fixed order of sequence acquisition, so while 1000 scans are available for the first sequence (the T1 structural image), fewer subjects are available for subsequent runs due to incomplete scanning sessions (e.g., lack of time or subject withdrawal). The two fMRI tasks (the fractal n-back task and the emotion identification task) were administered in a counter-balanced order across the course of the study. Log files for in-scanner task responses for the fMRI tasks are present in dbGaP as well.

As displayed in Table 1, the T1 and BOLD runs used standard product sequences. However, as described in more detail in our prior paper on the design of the PNC, several details regarding the diffusion weighted imaging sequence should be noted. In pediatric and clinical populations, the diffusion sequence is typically less well tolerated and perfusion imaging sequence should be noted. In pediatric and clinical populations, the diffusion sequence is typically less well tolerated.

<table>
<thead>
<tr>
<th>Sequence</th>
<th>TR/TE/TI (ms)</th>
<th>FOV (RL/AP) (mm)</th>
<th>Matrix (RL/AP/slices)</th>
<th>Slice thickness/gap (mm)</th>
<th>Flip angle (deg)</th>
<th>Reps</th>
<th>GRAPPA factor</th>
<th>BW/pixel (Hz)</th>
<th>PE direction</th>
<th>Acq time in dbGaP</th>
<th># Subjects</th>
</tr>
</thead>
<tbody>
<tr>
<td>MPRAGE</td>
<td>1810/2.5/1100</td>
<td>180/240</td>
<td>192/256/160</td>
<td>1/0</td>
<td>9</td>
<td>2</td>
<td>130</td>
<td>RL</td>
<td>3:28</td>
<td>1000</td>
<td></td>
</tr>
<tr>
<td>PCASL</td>
<td>4000/15/–</td>
<td>220/220</td>
<td>96/96/20</td>
<td>5/1</td>
<td>90/180</td>
<td>80</td>
<td>2</td>
<td>2604</td>
<td>AP</td>
<td>9:32</td>
<td>942</td>
</tr>
<tr>
<td>BD Map</td>
<td>1000/2.6/9+5.27/–</td>
<td>240/240</td>
<td>64/64/44</td>
<td>4/0</td>
<td>60</td>
<td>–</td>
<td>500</td>
<td>AP</td>
<td>1:04</td>
<td>1036</td>
<td>934</td>
</tr>
<tr>
<td>Emotion ID</td>
<td>3000/32/–</td>
<td>192/192</td>
<td>64/64/46</td>
<td>3/0</td>
<td>90</td>
<td>210</td>
<td>–</td>
<td>2056</td>
<td>AP</td>
<td>10:36</td>
<td>913</td>
</tr>
<tr>
<td>N-Back</td>
<td>3000/32/–</td>
<td>192/192</td>
<td>64/64/46</td>
<td>3/0</td>
<td>90</td>
<td>231</td>
<td>–</td>
<td>2056</td>
<td>AP</td>
<td>11:39</td>
<td>913</td>
</tr>
<tr>
<td>DTL</td>
<td>8100/82</td>
<td>240/240</td>
<td>128/128/70</td>
<td>2/0</td>
<td>90/180/180</td>
<td>35</td>
<td>3</td>
<td>2170</td>
<td>AP</td>
<td>5:24</td>
<td>885</td>
</tr>
<tr>
<td>DTI</td>
<td>8100/82</td>
<td>240/240</td>
<td>128/128/70</td>
<td>2/0</td>
<td>90/180/180</td>
<td>36</td>
<td>3</td>
<td>2170</td>
<td>AP</td>
<td>5:32</td>
<td>885</td>
</tr>
<tr>
<td>Resting FC</td>
<td>3000/32/–</td>
<td>192/192</td>
<td>64/64/46</td>
<td>3/0</td>
<td>90</td>
<td>124</td>
<td>–</td>
<td>2056</td>
<td>AP</td>
<td>6:18</td>
<td>883</td>
</tr>
</tbody>
</table>

### Data de-identification procedures

Genetic and phenotypic (clinical, cognitive and neuroimaging) data underwent a multi-step process with multiple encrypted identifiers as part of an anonymization process in order to de-identify participant data. The data anonymization process was setup such that no individual was allowed access to both identifiable phenotype data and clinical data. The encryption system is made up of 3 steps; two of the steps are in the form of a RSA encryption and the third step is in the form of a lookup table in a database connecting a second level encrypted ID to a 10 digit human readable subject ID. For the raw neuroimaging data, all identifying information was stripped from the image headers; demographic information including age (in months), sex, self-reported race, and the new final encrypted ID were written into this anonymized header.
Data access procedures

Unlike many other neuroimaging data repositories, genetic data is available for all PNC subjects. Due to resulting concerns regarding confidentiality, in collaboration with funding agencies it was decided that imaging, genetic, and phenotypic data would be shared jointly in dbGaP. The PNC is listed under the original project name: “Neurodevelopmental Genomics: Trajectories of Complex Phenotypes.” The full URL is http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000607.v1.p1.

As described in detail elsewhere (Mailman et al., 2007), dbGaP was created to be a general repository for sharing genetic and phenotypic data from large-scale studies in a secure manner. Accordingly, most of the access and sharing procedures for the PNC are governed by dbGaP policies; these are summarized briefly here. However, further detail can be found both in published manuscripts (Mailman et al., 2007; Walker et al., 2011) and also in extensive online guidance on the dbGaP website.

The dbGaP is designed to be a repository for both genotypic and phenotypic data. Each study receives a unique identifier within dbGaP (data type prefix: “phs”); the study accession ID for the PNC is phs000607.v1.p1. Within dbGaP there are specific data types for study documents (“phd”) including data dictionaries and protocol documents. Tables of phenotypic traits (“pht”) include individual phenotypic variables (“phv”), which are linked to study documents and data dictionaries via XML formatting. Genetic data (“phg”) is represented in matrix format. Version suffixes are supplied for each data type. Errors detected will be updated upon detection and annual updates. Large phenotypes such as the neuroimaging files in dcm format are compressed in .tar format. The data manifest for the PNC provides an orientation of data accessible via dbGaP.

The PNC data in dbGaP is accessible to qualified investigators, defined as an individual with PI credentials in eRA Commons. Individuals who do not have PI credentials can collaborate with PIs who may apply on their behalf. All users must complete a brief Data Access Request, which includes a Research Use Statement (2200 characters maximum) that summarizes project goals. Following access approval, the submitted Research Use Statement is made publicly available on the dbGaP project page for the PNC. A non-technical summary for the lay public is also required (1100 characters maximum). Data access requests must designate the appropriate institutional signing official as well as the local information technology director, who has the authority to vouch for the capability to conform to the data security policies of the dbGaP Data Use Certification. This Data Use Certification details that users will only use data in accordance with the proposal outlined in the Data Access Request; other research requires a separate Data Access Request. The term of use is 1 year, and can be renewed. Furthermore, approved users must pledge not to attempt to identify any individuals in the dataset, nor transfer the data to any individual not included in the initial Data Access Request; any inadvertent data release or security breach should be reported. While dbGaP does allow for a 1-year publication embargo period, this embargo expired January 31st, 2015.

Once users are granted access to the PNC data in dbGaP, they may download the data using the Aspera Connect utility, which is publicly available (http://downloads.asperasoft.com/downloads). Aspera Connect allows very large datasets to be downloaded from dbGaP through a FASP protocol that uses UDP, providing download rates of up to 1 gigabit per second. Furthermore, the utility has automatic checksum and bandwidth dialing capability to ensure transfer completion and minimize interruptions.

Future directions

The first 1000 subjects imaged as part of the PNC were released to dbGaP for public use. However, both cross-sectional (current n = 1601) and longitudinal (current n = 404) data acquisition are ongoing. Given this expanded sample, it is likely that the public PNC neuroimaging datasets may be expanded in the future. However, it is possible that certain data may not be made public, but reserved for use in analysis challenges as a test/validation dataset. Additionally, certain data from PNC participants was not placed in dbGaP for public use. This includes data from the electronic medical records and other potentially identifying information.

PNC data in dbGaP is a relatively static resource comprised of raw imaging data. While presently there are no resources to provide active ongoing support for all users of the repository, moving forward we hope to extend current data to include processed data, quality assurance information, and support for data management. Currently, such resources are available only for collaborative research. To facilitate such research, we have developed an internal system for managing, tracking, and servicing collaborations, with links to both REDCAP (subject variable) and XNAT (neuroimaging data) databases at UPenn.

Public interest in the PNC has been rapidly accelerating. The PNC data was placed in dbGaP in January 2014; as of January 2015 there have been 62 approved data use requests to access the PNC data. Many of these requests were related to RFA MH–15–400 (“Leveraging a Recovery Act Resource to Accelerate Research on Neurodevelopment”), which will provide 3 years of R01-level funding to several groups to perform integrative data analysis on publically available PNC data. The goal of this mechanism is to both accelerate discoveries regarding the neurodevelopmental origin of psychopathology and to stimulate the use of the PNC data within the wider neuroscience community. Through this mechanism and other ongoing research, the publicly available PNC data in dbGaP is therefore likely to become a major resource for neurodevelopmental research.

Disclosures

The authors report no disclosures.

Financial support

Supported by RC2 grants from the National Institute of Mental Health MH089983 and MH089924, as well as T32 MH019112 and U01HG006830. Additional support was provided by K23MH098130 to TDS, K01MH102609 to DRR, and K08MH79364 to MEC. Genotyping was funded by an Institutional Development Award to the Center for Applied Genomics from The Children’s Hospital of Philadelphia and a donation from Adele and Daniel Kuret.

Acknowledgments

Many thanks to the acquisition team, including Jeff Valdez, Raphael Gerraty, Nicholas DeLeo, and Elliot Yodh.

References
